TNF-α G308A gene polymorphism has an impact on renal function, microvascular permeability, organ involvement and severity of preeclampsia

Gynecologic and Obstetric Investigation

Volumn 78, Issue 3, 2014, Pages 150-161

  Zubor, Pavol ^a   Dokus, Karol ^a   Zigo, Imrich ^a   Skerenova, Maria ^a   Pullmann, Rudolf ^a   Danko, Jan ^a  

^a University Hospital in Martin   (Slovakia)

Author keywords

Complications; Polymorphism; Preeclampsia; Tumor necrosis factor

Indexed keywords

CREATINE; FIBRONECTIN; TUMOR NECROSIS FACTOR ALPHA; VASCULAR CELL ADHESION MOLECULE 1;

ADOLESCENT; ADULT; ALLELE; APGAR SCORE; ARTICLE; BIRTH WEIGHT; BLOOD VESSEL PERMEABILITY; BODY MASS; CONTROLLED STUDY; CREATININE CLEARANCE; DIASTOLIC BLOOD PRESSURE; DISEASE SEVERITY; DNA POLYMORPHISM; ENDOTHELIUM CELL; FEMALE; GENE FREQUENCY; GENOTYPE; GESTATIONAL AGE; GLOMERULUS FILTRATION; HETEROZYGOTE; HUMAN; KIDNEY FUNCTION; KIDNEY TUBULE ABSORPTION; MAJOR CLINICAL STUDY; MATERNAL SERUM; MICROVASCULAR PERMEABILITY; PREECLAMPSIA; PREGNANCY; PREGNANCY TERMINATION; PROMOTER REGION; PROTEIN BLOOD LEVEL; PROTEINURIA; SYSTOLIC BLOOD PRESSURE; URINARY EXCRETION; BLOOD; CAPILLARY PERMEABILITY; CASE CONTROL STUDY; GENETIC POLYMORPHISM; GENETICS; KIDNEY DISEASE; SEVERITY OF ILLNESS INDEX; THIRD TRIMESTER PREGNANCY; URINE; YOUNG ADULT;

ADOLESCENT; ADULT; ALLELES; CAPILLARY PERMEABILITY; CASE-CONTROL STUDIES; FEMALE; FIBRONECTINS; HUMANS; KIDNEY DISEASES; POLYMORPHISM, GENETIC; PRE-ECLAMPSIA; PREGNANCY; PREGNANCY TRIMESTER, THIRD; PROTEINURIA; SEVERITY OF ILLNESS INDEX; TUMOR NECROSIS FACTOR-ALPHA; VASCULAR CELL ADHESION MOLECULE-1; YOUNG ADULT;

EID: 84908670230     PISSN: 03787346     EISSN: 1423002X     Source Type: Journal    
DOI: 10.1159/000364865     Document Type: Article

References (68)

1. Tomas SZ, Prusac IK, Roje D, Tadin I: Trophoblast apoptosis in placentas from pregnancies complicated by preeclampsia. Gynecol Obstet Invest 2011; 71: 250-255.
2. Foidart JM, Schaaps JP, Chantraine F, Munaut C, Lorquet S: Dysregulation of anti-angiogenic agents (sFlt-1, PLGF, and sEndoglin) in preeclampsia - a step forward but not the definitive answer. J Reprod Immunol 2009; 82: 106-111.
3. Catarino C, Rebelo I, Belo L, Rocha S, Castro EB, Patrício B, Quintanilha A, Santos-Silva A: Fetal and maternal angiogenic/anti-angiogenic factors in normal and preeclamptic pregnancy. Growth Factors 2009; 27: 345-351.
4. Song C, Xie S, Wang J, Lian J, Diao B, Tang Y: Association of angiotensinogen gene polymorphisms and angiogenic factors with preeclampsia in Chinese women. Gynecol Obstet Invest 2013; 76: 64-68.
5. Hung TH, Burton GJ: Hypoxia and reoxygenation: a possible mechanism for placental oxidative stress in preeclampsia. Taiwan J Obstet Gynecol 2006; 45: 189-200.
6. Shin JK, Baek JC, Kang MY, Park JK, Lee SA, Lee JH, Choi WS, Paik WY: Proteomic analysis reveals an elevated expression of heat shock protein 27 in preeclamptic placentas. Gynecol Obstet Invest 2011; 71: 151-157.
7. Nejatizadeh A, Stobdan T, Malhotra N, Pasha MA: The genetic aspects of pre-eclampsia: achievements and limitations. Biochem Genet 2008; 46: 451-479.
8. Jonsson Y, Rubèr M, Matthiesen L, Berg G, Nieminen K, Sharma S, Ernerudh J, Ekerfelt C: Cytokine mapping of sera from women with preeclampsia and normal pregnancies. J Reprod Immunol 2006; 70: 83-91.
9. Cudihy D, Lee RV: The pathophysiology of pre-eclampsia: current clinical concepts. J Obstet Gynaecol 2009; 29: 576-582.
10. Xia Y, Kellems RE: Is preeclampsia an autoimmune disease? Clin Immunol 2009; 133: 1-12.
11. Sharma A, Satyam A, Sharma JB: Leptin, IL-10 and inflammatory markers (TNF-alpha, IL-6 and IL-8) in pre-eclamptic, normotensive pregnant and healthy non-pregnant women. Am J Reprod Immunol 2007; 58: 21-30.
12. Peraçoli JC, Rudge MV, Peraçoli MT: Tumor necrosis factor-alpha in gestation and puerperium of women with gestational hypertension and pre-eclampsia. Am J Reprod Immunol 2007; 57: 177-185.
13. Laskowska M, Leszczyńska-Gorzelak B, Laskowska K, Oleszczuk J: Evaluation of maternal and umbilical serum TNFalpha levels in preeclamptic pregnancies in the intrauterine normal and growth-restricted fetus. J Matern Fetal Neonatal Med 2006; 19: 347-351.
14. Altinova AE, Toruner F, Bozkurt N, Bukan N, Karakoc A, Yetkin I, Ayvaz G, Cakir N, Arslan M: Circulating concentrations of adiponectin and tumor necrosis factor-alpha in gestational diabetes mellitus. Gynecol Endocrinol 2007; 23: 161-165.
15. Curry AE, Thorsen P, Drews C, Schendel D, Skogstrand K, Flanders WD, Hougaard D, Olsen J, Vogel I: First-trimester maternal plasma cytokine levels, pre-pregnancy body mass index, and spontaneous preterm delivery. Acta Obstet Gynecol Scand 2009; 88: 332-342.
16. Daher S, Shulzhenko N, Morgun A, Mattar R, Rampim GF, Camano L, DeLima MG: Associations between cytokine gene polymorphisms and recurrent pregnancy loss. J Reprod Immunol 2003; 58: 69-77.
17. Hajeer AH, Hutchinson IV: Influence of TNFalpha gene polymorphisms on TNFalpha production and disease. Hum Immunol 2001; 62: 1191-1199.
18. Allen RD: Polymorphism of the human TNFalpha promoter - random variation or functional diversity? Mol Immunol 1999; 36: 1017-1027.
19. Canto-Cetina T, Canizales-Quinteros S, de la Chesnaye E, Coral-Vázquez R, Méndez JP, Canto P: Analysis of C-850T and G-308A polymorphisms of the tumor necrosis factoralpha gene in Maya-Mestizo women with preeclampsia. Hypertens Pregnancy 2007; 26: 283-291.
20. de Lima TH, Sass N, Mattar R, Moron AF, Torloni MR, Franchim CS, Daher S: Cytokine gene polymorphisms in preeclampsia and eclampsia. Hypertens Res 2009; 32: 565-569.
21. Dizon-Townson DS, Major H, Ward K: A promoter mutation in the tumor necrosis factor alpha gene is not associated with preeclampsia. J Reprod Immunol 1998; 38: 55-61.
22. Freeman DJ, McManus F, Brown EA, Cherry L, Norrie J, Ramsay JE, Clark P, Walker ID, Sattar N, Greer IA: Short- and long-term changes in plasma inflammatory markers associated with preeclampsia. Hypertension 2004; 44: 708-714.
23. Haggerty CL, Ferrell RE, Hubel CA, Markovic N, Harger G, Ness RB: Association between allelic variants in cytokine genes and preeclampsia. Am J Obstet Gynecol 2005; 193: 209-215.
24. Chen G, Wilson R, Wang SH, Zheng HZ, Walker JJ, McKillop JH: Tumour necrosis factor- alpha (TNF-alpha) gene polymorphism and expression in pre-eclampsia. Clin Exp Immunol 1996; 104: 154-159.
25. Kaiser T, Grehan M, Brennecke SP, Moses EK: Association of the TNF2 allele with eclampsia. Gynecol Obstet Invest 2004; 57: 204-209.
26. Lachmeijer AM, Crusius JB, Pals G, Dekker GA, Arngrímsson R, ten Kate LP: Polymorphisms in the tumor necrosis factor and lymphotoxin- alpha gene region and preeclampsia. Obstet Gynecol 2001; 98: 612-619.
27. Livingston JC, Park V, Barton JR, Elfering S, Haddad B, Mabie WC, Quasney M, Sibai BM: Lack of association of severe preeclampsia with maternal and fetal mutant alleles for tumor necrosis factor alpha and lymphotoxin alpha genes and plasma tumor necrosis factor alpha levels. Am J Obstet Gynecol 2001; 184: 1273-1277.
28. Mirahmadian M, Kalantar F, Heidari G, Safdarian L, Mansouri R, Amirzargar AA: Association of tumor necrosis factor-alpha and interleukin-10 gene polymorphisms in Iranian patients with pre-eclampsia. Am J Reprod Immunol 2008; 60: 179-185.
29. Pazarbaşi A, Kasap M, Güzel AI, Kasap H, Onbaşioʇlu M, Ozbakir B, Demirkazik A, Ozgünen FT, Gürtunç E: Polymorphisms in the tumor necrosis factor-alpha gene in Turkish women with pre-eclampsia and eclampsia. Acta Med Okayama 2007; 61: 153-160.
30. Saarela T, Hiltunen M, Helisalmi S, Heinonen S, Laakso M: Tumour necrosis factor-alpha gene haplotype is associated with pre-eclampsia. Mol Hum Reprod 2005; 11: 437-440.
31. Stonek F, Bentz EK, Hafner E, Metzenbauer M, Philipp K, Hefler LA, Tempfer CB: A tumor necrosis factor-alpha promoter polymorphism and pregnancy complications: results of a prospective cohort study in 1652 pregnant women. Reprod Sci 2007; 14: 425-429.
32. Stonek F, Hafner E, Metzenbauer M, Katharina S, Stümpflen I, Schneeberger C, Zeisler H, Husslein P, Philipp K: Absence of an association of tumor necrosis factor (TNF)-alpha G308A, interleukin-6 (IL-6) G174C and interleukin-10 (IL-10) G1082A polymorphism in women with preeclampsia. J Reprod Immunol 2008; 77: 85-90.
33. Bombell S, McGuire W: Tumour necrosis factor (-308A) polymorphism in pre-eclampsia: meta-analysis of 16 case-control studies. Aust N Z J Obstet Gynaecol 2008; 48: 547-551.
34. Daher S, Sass N, Oliveira LG, Mattar R: Cytokine genotyping in preeclampsia. Am J Reprod Immunol 2006; 55: 130-135.
35. Molvarec A, Jermendy A, Nagy B, Kovács M, Várkonyi T, Hupuczi P, Prohászka Z, Rigó J Jr: Association between tumor necrosis factor (TNF)-alpha G-308A gene polymorphism and preeclampsia complicated by severe fetal growth restriction. Clin Chim Acta 2008; 392: 52-57.
36. Chen YP, Pfab T, Slowinski T, Richter CM, Godes M, Hocher B: Impact of genetic variation of tumor necrosis factor-alpha on gestational hypertension. Chin Med J 2006; 119: 719-724.
37. Pfab T, Chen YP, Slowinski T, Richter CM, Godes M, Arck PC, Halle H, Hocher B: Impact of genes related to immune tolerance and inflammation (tumour necrosis factor-alpha, interleukin-6) on blood pressure, protein excretion and oedema in pregnancy. J Hypertens 2005; 23: 2187-2191.
38. Zhang H, Park Y, Wu J, Chen XP, Lee S, Yang J, Dellsperger KC, Zhang C: Role of TNF-alpha in vascular dysfunction. Clin Sci (Lond) 2009; 116: 219-230.
39. Budak E, Madazli R, Aksu MF, Benian A, Gezer A, Palit N, Yildizfer F: Vascular cell adhesion molecule-1 (VCAM-1) and leukocyte activation in pre-eclampsia and eclampsia. Int J Gynaecol Obstet 1998; 63: 115-121.
40. Kim SY, Ryu HM, Yang JH, Kim MY, Ahn HK, Lim HJ, Shin JS, Woo HJ, Park SY, Kim YM, Kim JW, Cho EH: Maternal serum levels of VCAM-1, ICAM-1 and E-selectin in preeclampsia. J Korean Med Sci 2004; 19: 688-692.
41. Chavarría ME, Lara-González L, González- Gleason A, Sojo I, Reyes A: Maternal plasma cellular fibronectin concentrations in normal and preeclamptic pregnancies: a longitudinal study for early prediction of preeclampsia. Am J Obstet Gynecol 2002; 187: 595-601.
42. Ostlund E, Hansson LO, Bremme K: Fibronectin is a marker for organ involvement and may reflect the severity of preeclampsia. Hypertens Pregnancy 2001; 20: 79-87.
43. Yoon JJ, Lee YJ, Kim JS, Kim JS, Lee HS: Effect of Zanthoxylum schinifolium on TNF-alphainduced vascular inflammation in human umbilical vein endothelial cells. Vascul Pharmacol 2009; 50: 200-207.
44. Report of the National High Blood Pressure Education Program Working Group on High Blood Pressure in Pregnancy. Am J Obstet Gynecol 2000; 183:S1-S22.
45. Higham MA, Pride NB, Alikhan A, Morrell NW: Tumour necrosis factor-alpha gene promoter polymorphism in chronic obstructive pulmonary disease. Eur Respir J 2000; 15: 281-284.
46. Tahergorabi Z, Khazaei M: The relationship between inflammatory markers, angiogenesis, and obesity. ARYA Atheroscler 2013; 9: 247-253.
47. Rodríguez-Hernández H, Simental-Mendía LE, Rodríguez-Ramírez G, Reyes-Romero MA: Obesity and inflammation: epidemiology, risk factors, and markers of inflammation. Int J Endocrinol 2013; 2013: 678159.
48. Jia RZ, Qian YJ, Zhang X, Ding HJ, Wu HQ, Shao KM: Contribution of dysfunction of maternal hemodynamics to renal impairment in preeclampsia. Gynecol Obstet Invest 2013; 76: 95-99.
49. Slungaard A, Vercellotti GM, Walker G, Nelson RD, Jacob HS: Tumor necrosis factor alpha/ cachectin stimulates eosinophil oxidant production and toxicity towards human endothelium. J Exp Med 1990; 171: 2025-2041.
50. Chen G, Wilson R, Cumming G, Walker JJ, McKillop JH: Production of prostacyclin and thromboxane A 2 in mononuclear cells from preeclamptic women. Am J Obstet Gynecol 1993; 169: 1106-1111.
51. Chen G, Wilson R, Cumming G, Walker JJ, Smith WE, McKillop JH: Intracellular and extracellular antioxidant buffering levels in erythrocytes from pregnancy-induced hypertension. J Hum Hypertens 1994; 8: 37-42.
52. Iademarco MF, McQuillan JJ, Rosen GD, Dean DC: Characterization of the promoter for vascular cell adhesion molecule-1 (VCAM-1). J Biol Chem 1992; 267: 16323-16329.
53. Scarpati EM, Sadler JE: Regulation of endothelial cell coagulant properties. Modulation of tissue factor, plasminogen activator inhibitors, and thrombomodulin by phorbol 12-myristate 13-acetate and tumor necrosis factor. J Biol Chem 1989; 264: 20705-20713.
54. Yoshizumi M, Perrella MA, Burnett JC Jr, Lee ME: Tumor necrosis factor downregulates an endothelial nitric oxide synthase mRNA by shortening its half-life. Circ Res 1993; 73: 205-209.
55. Austgulen R, Lien E, Vince G, Redman CW: Increased maternal plasma levels of soluble adhesion molecules (ICAM-1, VCAM-1, Eselectin) in preeclampsia. Eur J Obstet Gynecol Reprod Biol 1997; 71: 53-58.
56. Heyl W, Handt S, Reister F, Gehlen J, Mittermayer C, Rath W: The role of soluble adhesion molecules in evaluating endothelial cell activation in preeclampsia. Am J Obstet Gynecol 1999; 180: 68-72.
57. Meekins JW, McLaughlin PJ, West DC, Mc-Fadyen IR, Johnson PM: Endothelial cell activation by tumour necrosis factor-alpha (TNF-alpha) and the development of pre-eclampsia. Clin Exp Immunol 1994; 98: 110-114.
58. Vince GS, Starkey PM, Austgulen R, Kwiatkowski D, Redman CW: Interleukin-6, tumour necrosis factor and soluble tumour necrosis factor receptors in women with pre-eclampsia. Br J Obstet Gynaecol 1995; 102: 20-25.
59. Visser W, Beckmann I, Knook MA, Wallenburg HC: Soluble tumor necrosis factor receptor II and soluble cell adhesion molecule 1 as markers of tumor necrosis factor-alpha release in preeclampsia. Acta Obstet Gynecol Scand 2002; 81: 713-719.
60. von Versen-Hoeynck FM, Hubel CA, Gallaher MJ, Gammill HS, Powers RW: Plasma levels of inflammatory markers neopterin, sialic acid, and C-reactive protein in pregnancy and preeclampsia. Am J Hypertens 2009; 22: 687-692.
61. Anim-Nyame N, Gamble J, Sooranna SR, Johnson MR, Steer PJ: Microvascular permeability is related to circulating levels of tumour necrosis factor-alpha in pre-eclampsia. Cardiovasc Res 2003; 58: 162-169.
62. Brubaker DB, Ross MG, Marinoff D: The function of elevated plasma fibronectin in preeclampsia. Am J Obstet Gynecol 1992; 166: 526-531.
63. Madazli R, Aydin S, Uludag S, Vildan O, Tolun N: Maternal plasma levels of cytokines in normal and preeclamptic pregnancies and their relationship with diastolic blood pressure and fibronectin levels. Acta Obstet Gynecol Scand 2003; 82: 797-802.
64. Guven MA, Coskun A, Ertas IE, Aral M, Zencirci B, Oksuz H: Association of maternal serum CRP, IL-6, TNF-alpha, homocysteine, folic acid and vitamin B 12 levels with the severity of preeclampsia and fetal birth weight. Hypertens Pregnancy 2009; 28: 190-200.
65. Phocas I, Rizos D, Papoulias J, Xyni K, Sarandakou A, Salamalekis E: A comparative study of serum soluble vascular cell adhesion molecule-1 and soluble intercellular adhesion molecule-1 in preeclampsia. J Perinatol 2000; 20: 114-119.
66. Krauss T, Kuhn W, Lakoma C, Augustin HG: Circulating endothelial cell adhesion molecules as diagnostic markers for the early identification of pregnant women at risk for development of preeclampsia. Am J Obstet Gynecol 1997; 177: 443-449.
67. Krauss T, Emons G, Kuhn W, Augustin HG: Predictive value of routine circulating soluble endothelial cell adhesion molecule measurements during pregnancy. Clin Chem 2002; 48: 1418-1425.
68. Dane C, Buyukasik H, Dane B, Yayla M: Maternal plasma fibronectin and advanced oxidative protein products for the prediction of preeclampsia in high risk pregnancies: a prospective cohort study. Fetal Diagn Ther 2009; 26: 189-194.